Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Evaluate the effectiveness and safety of Lactobacillus delbrueckii subsp. bulgaricus LB42 as a food supplement compared to a placebo in improving intestinal and immune functions in healthy adults.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Probiotic group | Experimental | Lactobacillus delbrueckii subsp. bulgaricus LB42 (30 billion CFU/day, 3g) was administered daily for 8 weeks. Store in a cool and dry place. |
|
| Placebo group | Placebo Comparator | Every day to give 3g dextrin intervention for 8 weeks. Store in a cool and dry place. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Probiotic group | Dietary Supplement | The experimental phase of this study will last 8 weeks and each subject will receive 3 follow-up visits (week 0, week 4, week 8). |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in the concentration of LL-37 in feces before and after intervention. | Detected by Enzyme-Linked Immunosorbent Assay (ELISA). | Week 0 and Week 8 |
| Measure | Description | Time Frame |
|---|---|---|
| Change in the composition of fecal microbiota before and after intervention. | Analyzed by 16s RNA sequencing. | Week 0 and Week 8 |
| Change in the concentration of calprotectin in feces before and after intervention. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Xu fei | Zhengzhou | Henan | 210095 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo group | Dietary Supplement | The experimental phase of this study will last 8 weeks and each subject will receive 3 follow-up visits (week 0, week 4, week 8). |
|
Detected by Enzyme-Linked Immunosorbent Assay (ELISA).
| Week 0 and Week 8 |